Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 15325 | 16.8359 |
09:34 ET | 3347 | 16.83 |
09:36 ET | 3259 | 16.9 |
09:38 ET | 1460 | 16.93 |
09:39 ET | 30095 | 16.9944 |
09:41 ET | 3100 | 17.045 |
09:43 ET | 3021 | 17.0788 |
09:45 ET | 10415 | 17.0762 |
09:48 ET | 8811 | 16.99 |
09:50 ET | 1017 | 16.98 |
09:52 ET | 2250 | 16.99 |
09:54 ET | 7000 | 16.9499 |
09:56 ET | 2752 | 16.93 |
09:57 ET | 4900 | 16.91 |
09:59 ET | 1130 | 16.95 |
10:01 ET | 1700 | 16.93 |
10:03 ET | 2988 | 16.91 |
10:06 ET | 300 | 16.95 |
10:08 ET | 1885 | 16.905 |
10:10 ET | 3527 | 16.91 |
10:12 ET | 8631 | 16.92 |
10:14 ET | 2616 | 16.86 |
10:15 ET | 14532 | 16.91 |
10:17 ET | 100 | 16.94 |
10:19 ET | 1825 | 16.95 |
10:21 ET | 7700 | 16.96 |
10:24 ET | 24310 | 16.945 |
10:26 ET | 2282 | 16.895 |
10:28 ET | 864 | 16.89 |
10:30 ET | 8896 | 16.865 |
10:32 ET | 6600 | 16.885 |
10:33 ET | 800 | 16.89 |
10:35 ET | 7288 | 16.88 |
10:37 ET | 5122 | 16.83 |
10:39 ET | 300 | 16.855 |
10:42 ET | 3717 | 16.83 |
10:44 ET | 2547 | 16.815 |
10:46 ET | 7737 | 16.8459 |
10:48 ET | 1501 | 16.84 |
10:50 ET | 4690 | 16.81 |
10:51 ET | 3994 | 16.8 |
10:53 ET | 1500 | 16.815 |
10:55 ET | 4672 | 16.76 |
10:57 ET | 12383 | 16.8 |
11:00 ET | 11809 | 16.78 |
11:02 ET | 2328 | 16.8 |
11:04 ET | 2465 | 16.75 |
11:06 ET | 7333 | 16.7174 |
11:08 ET | 4718 | 16.68 |
11:09 ET | 8791 | 16.7 |
11:11 ET | 1400 | 16.705 |
11:13 ET | 3814 | 16.68 |
11:15 ET | 15229 | 16.63 |
11:18 ET | 10352 | 16.69 |
11:20 ET | 300 | 16.68 |
11:22 ET | 1300 | 16.61 |
11:24 ET | 8230 | 16.5995 |
11:26 ET | 6264 | 16.6051 |
11:27 ET | 1482 | 16.6 |
11:29 ET | 1400 | 16.59 |
11:31 ET | 4350 | 16.58 |
11:33 ET | 2453 | 16.6 |
11:36 ET | 4400 | 16.59 |
11:38 ET | 6550 | 16.57 |
11:40 ET | 3250 | 16.64 |
11:42 ET | 18317 | 16.63 |
11:44 ET | 1228 | 16.62 |
11:45 ET | 1200 | 16.64 |
11:47 ET | 100 | 16.64 |
11:49 ET | 6445 | 16.735 |
11:51 ET | 5218 | 16.74 |
11:54 ET | 7550 | 16.76 |
11:56 ET | 1418 | 16.7501 |
11:58 ET | 200 | 16.75 |
12:00 ET | 1964 | 16.7 |
12:02 ET | 1500 | 16.71 |
12:03 ET | 100 | 16.72 |
12:05 ET | 5309 | 16.66 |
12:07 ET | 600 | 16.64 |
12:09 ET | 200 | 16.63 |
12:14 ET | 9000 | 16.64 |
12:16 ET | 1908 | 16.695 |
12:18 ET | 100 | 16.69 |
12:20 ET | 2406 | 16.67 |
12:21 ET | 1056 | 16.655 |
12:23 ET | 1980 | 16.6688 |
12:25 ET | 1473 | 16.68 |
12:27 ET | 500 | 16.67 |
12:30 ET | 2236 | 16.68 |
12:32 ET | 4600 | 16.68 |
12:34 ET | 2200 | 16.68 |
12:36 ET | 4700 | 16.68 |
12:38 ET | 2425 | 16.67 |
12:39 ET | 1100 | 16.66 |
12:41 ET | 2800 | 16.63 |
12:43 ET | 1587 | 16.64 |
12:45 ET | 3502 | 16.65 |
12:48 ET | 1700 | 16.65 |
12:50 ET | 1327 | 16.65 |
12:52 ET | 600 | 16.64 |
12:54 ET | 700 | 16.63 |
12:56 ET | 1133 | 16.62 |
12:57 ET | 986 | 16.63 |
12:59 ET | 4586 | 16.645 |
01:01 ET | 1300 | 16.64 |
01:03 ET | 400 | 16.635 |
01:06 ET | 3395 | 16.59 |
01:08 ET | 8385 | 16.62 |
01:10 ET | 4914 | 16.62 |
01:12 ET | 4482 | 16.625 |
01:14 ET | 2417 | 16.61 |
01:15 ET | 800 | 16.595 |
01:17 ET | 3399 | 16.5659 |
01:19 ET | 2917 | 16.56 |
01:21 ET | 1831 | 16.565 |
01:24 ET | 8234 | 16.59 |
01:26 ET | 1697 | 16.59 |
01:28 ET | 1311 | 16.6 |
01:30 ET | 2565 | 16.59 |
01:32 ET | 1095 | 16.5959 |
01:33 ET | 2760 | 16.59 |
01:35 ET | 3351 | 16.575 |
01:37 ET | 7068 | 16.54 |
01:39 ET | 1991 | 16.52 |
01:42 ET | 9202 | 16.495 |
01:44 ET | 32311 | 16.4744 |
01:46 ET | 6293 | 16.49 |
01:48 ET | 2000 | 16.49 |
01:50 ET | 1270 | 16.49 |
01:51 ET | 1101 | 16.48 |
01:53 ET | 3376 | 16.45 |
01:55 ET | 4932 | 16.42 |
01:57 ET | 7200 | 16.44 |
02:00 ET | 2331 | 16.4419 |
02:02 ET | 2658 | 16.44 |
02:04 ET | 900 | 16.44 |
02:06 ET | 1100 | 16.445 |
02:08 ET | 6180 | 16.4011 |
02:09 ET | 2277 | 16.42 |
02:11 ET | 4800 | 16.44 |
02:13 ET | 4346 | 16.47 |
02:15 ET | 10052 | 16.48 |
02:18 ET | 3423 | 16.51 |
02:20 ET | 1872 | 16.49 |
02:22 ET | 3695 | 16.48 |
02:24 ET | 5120 | 16.505 |
02:26 ET | 4072 | 16.48 |
02:27 ET | 1000 | 16.47 |
02:29 ET | 3770 | 16.47 |
02:31 ET | 2217 | 16.45 |
02:33 ET | 200 | 16.455 |
02:36 ET | 4464 | 16.455 |
02:38 ET | 1212 | 16.44 |
02:40 ET | 1266 | 16.44 |
02:42 ET | 1655 | 16.41 |
02:44 ET | 7652 | 16.3737 |
02:45 ET | 8511 | 16.42 |
02:47 ET | 900 | 16.42 |
02:49 ET | 3633 | 16.405 |
02:51 ET | 1600 | 16.38 |
02:54 ET | 3483 | 16.375 |
02:56 ET | 1876 | 16.39 |
02:58 ET | 1000 | 16.42 |
03:00 ET | 5080 | 16.43 |
03:02 ET | 3011 | 16.38 |
03:03 ET | 3159 | 16.35 |
03:05 ET | 6744 | 16.375 |
03:07 ET | 3272 | 16.38 |
03:09 ET | 1574 | 16.4 |
03:12 ET | 14276 | 16.395 |
03:14 ET | 4968 | 16.39 |
03:16 ET | 4247 | 16.375 |
03:18 ET | 14337 | 16.37 |
03:20 ET | 6143 | 16.3781 |
03:21 ET | 6342 | 16.375 |
03:23 ET | 5499 | 16.39 |
03:25 ET | 9053 | 16.39 |
03:27 ET | 2491 | 16.385 |
03:30 ET | 11492 | 16.39 |
03:32 ET | 24754 | 16.38 |
03:34 ET | 4668 | 16.4 |
03:36 ET | 2908 | 16.395 |
03:38 ET | 54153 | 16.355 |
03:39 ET | 6396 | 16.355 |
03:41 ET | 14783 | 16.395 |
03:43 ET | 9868 | 16.4 |
03:45 ET | 17700 | 16.375 |
03:48 ET | 12478 | 16.355 |
03:50 ET | 19847 | 16.315 |
03:52 ET | 34846 | 16.27 |
03:54 ET | 18274 | 16.2977 |
03:56 ET | 24022 | 16.275 |
03:57 ET | 46255 | 16.27 |
03:59 ET | 37485 | 16.3 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 2.5B | 73.9x | --- |
Twist Bioscience Corp | 2.4B | -12.5x | --- |
Arrowhead Pharmaceuticals Inc | 2.9B | -5.4x | --- |
Vericel Corp | 2.3B | 4,989.5x | --- |
ADMA Biologics Inc | 2.2B | -468.1x | --- |
Maravai LifeSciences Holdings Inc | 2.2B | -8.7x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.30 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 73.9x |
Price/Sales (TTM) | 8.7 |
Price/Cash Flow (TTM) | 60.9x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.